Cagri+Sema (5mg+5mg) – 10mg (10 vials)

Cagri + Sema – 5mg + 5mg – 10mg – 10 Vials

Product Overview

Cagri + Sema is a combination of cagrilintide and semaglutide, two compounds investigated for their roles in appetite regulation and metabolic processes.

Cagrilintide is a long-acting amylin analogue, while semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. The combination has been investigated in clinical research, but this does not establish the safety or approval of every combined formulation or vial presentation.

This listing describes a product labeled with 5mg of each compound, giving a combined labeled amount of 10mg.

Product Details

• Product Name: Cagri + Sema
• Active Ingredients: Cagrilintide + Semaglutide
• Listed Composition: 5mg + 5mg
• Combined Listed Amount: 10mg
• Package Quantity: 10 vials
• Product Category: Investigational Peptide Combination
• Formulation: Confirm with supplier
• Manufacturer: Confirm with supplier
• Storage Requirements: Follow verified manufacturer documentation

Scientific Background

Cagrilintide is an amylin analogue studied for its effects on appetite-related signaling and metabolic regulation.

Semaglutide acts on GLP-1 receptors and has approved prescription formulations for specific medical indications. Its established uses do not automatically apply to unverified combination products.

The combination of cagrilintide and semaglutide has been investigated in clinical studies. However, the evidence and regulatory status of a particular combination product must be assessed separately from those of the individual compounds.

Supplier Verification

Before publishing or distributing this product, confirm:

• Whether 5mg + 5mg applies to each vial or the entire package
• The exact amount of each active ingredient
• The formulation and concentration
• Manufacturer identity and batch information
• Available quality and composition documentation
• Storage and handling requirements
• Applicable regulatory authorization and restrictions

Important Safety and Regulatory Information

Semaglutide is a prescription medicine in certain approved formulations, while cagrilintide remains investigational. A combination product should not be presented as an approved medicine unless its specific formulation has the required authorization.

This listing is informational only and is not medical advice, a dosing guide, or a recommendation for self-administration. Do not make unsupported claims about weight loss, treatment outcomes, safety, purity, or regulatory approval. Verify the product’s identity, documentation, and legal status before making further claims.